CHMP Issues Positive Opinion To Expand Jardiance®, Synjardy® And Glyxambi® Labels To Include Positive Effects On Cardiovascular And Renal Outcomes

2020-08-17T20:55:47-07:00Industry News, Regulatory|

INGELHEIM, Germany & INDIANAPOLIS–(BUSINESS WIRE)–Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency (EMA) [...]

Novo’s oral semaglutide bests Lilly and Boehringer Ingelheim’s Jardiance in phase 3, but questions remain

2020-08-17T20:58:07-07:00Industry News|

Even as Novo Nordisk works to steal diabetes market share with its new GLP-1 drug Ozempic, it’s advancing an oral [...]

Go to Top